Using counterflow centrifugation elutriation (CCE) lymphocytes can be separated from CD34
GVHD; CD34; CAFC assay; allogeneic stem cell transplantation Extensive T cell depletion of transplants is the most effective way to reduce the incidence and severity of GVHD but is associated with an increased risk of graft failure and relapse after transplantation. 1, 2 During the last decade many methods of T cell depletion have been developed. These include MoAb conjugated to toxins or magnetic beads, or in combination with complement, and soybean lectins and sheep E-rosetting. [3] [4] [5] [6] [7] The depletion efficacy may vary considerably resulting in an inconsistently low T cell number in the graft.
Although a decline of T cells in the graft reduces the severity of GVHD, it is associated with a higher probability of graft rejection. 1, 8 This implies that in the graft the number of immunocompetent lymphocytes of the donor should be in balance with the residual chemo-radiotherapy-resistant lymphocytes in the recipient. The outcome of allogeneic transplantation would therefore improve considerably if the number of T cells/kg body weight could be adapted to each individual patient. Extensive elimination may simultaneously deplete populations such as NK cells which are likely to be involved in graft-versus-leukemia activity. This is manifested in higher relapse rates. The preferred approach is a technique that allows control of the separation process and that can be adapted to each individual patient.
Separation of cells by CCE is based on sedimentation velocity due to differences in cell size and density of lymphocytes and hematopoietic progenitor cells. 9 CCE has been successfully applied to deplete T cells in BMT as pioneered in our center. [10] [11] [12] [13] [14] [15] [16] [17] The incidence of both graft failure and relapse in recipients of T cell-depleted grafts using CCE compares favorably with other methods of T cell depletion. [10] [11] [12] [13] This may be due to the number of remaining lymphocytes in the graft after T cell depletion resulting in a sufficient anti-leukemia activity. 18 Less clinical experience exists with the use of CCE to deplete T cells from PBSC after mobilization with G-CSF. Recent experimental data showed that the separation of PB progenitors is comparable with those of BM progenitors. 19, 20 The capacity for engraftment is traditionally based on the number of CFU-GM in the graft. It is assumed that the presence of high numbers of CFU-GM in the graft guarantees sufficient pluripotent stem cells for complete long-term repopulation. Clinical trials in which selected CD34
+ cells were infused have demonstrated that this population is responsible for hematopoietic reconstitution. 21, 22 Previous studies have documented a correlation between the number of reinfused CD34
+ cells and time to hematopoietic recovery. [23] [24] [25] However, these parameters may be unfit to predict engraftment when the graft is manipulated by purging. Indeed, donor progenitor cells are unlikely to contribute to immediate and permanent engraftment in mouse models. 26, 27 In addition, small subpopulations of CD34-positive cells (eg CD34 + CD33 − ) are assumed to contain virtually all the immature progenitor cells that initiate long-term hematopoietic engraftment. Depending on the depletion technique these cells may be eliminated simultaneously with T cells.
Though CCE results in the recovery of most CFU-GM and CD34
+ cells from BM, as well from PBSC transplants, some investigators suggested that this technique may remove substantial numbers of immature progenitors from the transplant. 19, 28, 29 However, other studies, including preliminary data of our separations, showed contrary results both in BMT and PBSCT. 20, 30, 31 These different results might be explained by variations in CCE equipment and CCE procedures used in the different studies.
In the present study we investigated the separation process of the Curameé 3000 elutriator that has been extensively applied in our institute to enrich BM and PBSC transplants of HLA-identical sibling donors in approximately 500 stem cell transplants. The separation profiles as well as the recoveries of lymphocytes and mature and immature progenitor cells of BM and PB was studied. Lymphocyte populations and CD34-positive subpopulations were determined by means of flow cytometric analysis. The proliferative capacity of more mature progenitors was quantified by clonogenic assays for CFU-GM, CFU-GEMM and BFU-E and of immature progenitors by the CAFC assay. 32 We found that progenitors are efficiently separated from other cells without substantial loss of mature and immature progenitor cells.
Materials and methods

BM and PBSC collection and mononuclear cell separation
BM was harvested from 16 healthy HLA-identical sibling donors of a median age of 43 years (range 19-64 years) under complete anesthesia. The BM harvest (approximately 25 × 10 9 nucleated cells) was anticoagulated by collecting cells in 10% ACD-A and 5 IU/ml heparin. After fat and plasma extraction by centrifugation, mononuclear cells (MNC) were isolated by density flotation separation in Percoll (Pharmacia, Uppsala, Sweden) gradients as described previously. 33 BM was mixed with 90% Percoll solution obtaining a density of 1.085 g/l. This suspension was pumped under a 1.073 g/l Percoll layer in 250 ml bottles. After centrifugation the 1.073 g/l interphase cells were obtained by pushing out the complete gradient by using high density glucose solution (50% glucose). The cells were washed and loaded in the CCE chambers.
Twelve healthy HLA-identical sibling donors of a median age of 47 years (range 25-56 years) were treated with G-CSF (10 g/kg body weight) for 5 to 6 days prior to apheresis in order to mobilize their stem cells (PBSC). Cells were obtained by harvesting of 5 to 10 l blood equivalents by means of a Fenwal CS3000 cell separator (Baxter Healthcare, Deerfield, IL, USA) on each of 2 consecutive days. Each day approximately 30 × 10 9 cells were collected. Contaminating erythrocytes and granulocytes were removed by Percoll gradients (1.073 g/l) in 250 ml bottles. Interphase MNC were collected and further separated in the elutriation chambers.
Counterflow centrifugation elutriation (CCE)
Interphase MNC were separated in a four-chamber CCE rotor (Curameé 3000 system; Dijkstra Vereenigde BV, Amsterdam, The Netherlands) under constant control of the outflow by using a computerized scatter-monitor device and a speed tuned stroboscopic light as described previously. 9 Briefly, cells were loaded up to 2 × 10 9 cells per chamber under a constant flow rate. Glucose phosphate buffer supplemented with 1% human serum albumin (HSA; CLB, Amsterdam, The Netherlands) was used as elutriant. By reducing the rotor speed stepwise approximately 13 consecutive gradually more lymphocyte-depleted fractions and the maximally lymphocyte-depleted RO fraction were collected.
Flow cytometric analysis of CCE fractions
The number of T cells (CD3 + ), B cells (CD19 + ) and NK cells (CD3 − /CD56 + ) as well as the number of progenitor/stem cells (CD34 + ) in each fraction of CCE were determined by using dual color immunofluorescence flow cytometry. Cells (1 × 10 6 ) from each fraction were incubated with the following combinations of fluorochrome-labeled MoAb, CD3-FITC (UCHT1; DAKO, Glostrup, Denmark)/CD19-PE (HD37; DAKO), and CD3-FITC/CD56-PE (B159; Coulter-Immunotech, Marseille, France) to recognize T, B and NK cells, respectively, and by CD34-PE (class III recognizing MoAb 581; CoulterImmunotech)/CD45-FITC (J33, Coulter-Immunotech) to stain progenitor cells.
In order to study different progenitor cell subpopulations CD34-PE or CD34-PE-Cy5 (Coulter-Immunotech) was combined additionally with CD13-PE or CD13-FITC (WM-47, DAKO), CD38-PE (HB-7; Becton Dickinson, San Jose, CA, USA), anti-HLA-DR-FITC (CR3/43; DAKO), CD7-FITC (BB-7; IQP, Groningen, The Netherlands) and CD19-PE (HD37; DAKO). Cells were incubated for 30 min at 4°C. Remaining erythrocytes were lysed by using FACS lysing solution (Becton Dickinson) for 10 min at room temperature. Cells were washed in PBS supplemented with 1% bovine serum albumin and fixed with 1% paraformaldehyde. Cells were analyzed for immunofluorescence in a Coulter Epics XL flow cytometer (Coulter Corporation, Hialeah, FL, USA). Lymphocyte subpopulations were determined by gating on forward scatter and fluorescence whereas progenitor cells were measured by sequential gating on CD45-FITC against side scatter (SSC) followed by CD34 against SSC (ISHAGE protocol; Ref. 34) . For a reliable determination of CD34 + populations at least 100 000 cells were analyzed in the CD45 gate and at least 100 events were collected within the CD34 + gate. To study the recoveries of T cells and progenitor cells after the separation procedures the numbers of CD3-and CD34-positive cells were also assessed in the initial harvest, the lymphocyte and progenitor cell fractions, and the compiled graft after CCE.
Composition of the stem cell grafts
MNC from BM could be depleted of lymphocytes in one CCE run, whereas MNC from PBSC transplants were separated in two runs on each of 2 consecutive days. Several T cell fractions from each run were added to the RO fraction to obtain a graft containing approximately 0.7 × 10 6 T cells/kg body weight of the BM recipients and 4 × 10 6 T cells/kg body weight of the PBSC recipients. The lymphocyte fractions leaving the rotor just prior to the RO fraction were used for the T cell adaptation. With this technique it is permitted to add an appropriate number of T cells to each graft.
Progenitor cell assays
The number of different progenitor cells in the harvest, CCE fractions and the graft were also assessed by semisolid clonogenic assays for CFU-GM, BFU-E and CFU-GEMM. To assess CFU-GM cells were plated in 35-mm, Petri dishes (Costar, Cambridge, MA, USA) containing Bacto-Agar 0.3% (Difco Labs, Detroit, MI, USA) and Iscove's medium (IMDM; Gibco, Long Island, NY, USA) supplemented with 20% FCS (Hyclone Labs, Logan, UT, USA) and recombinant growth factors, IL3 (Sandoz Pharma, Basel, Switzerland), GM-CSF (Sandoz) and G-CSF (Amgen, Thousand Oaks, CA, USA). 35 To assess BFU-E and CFU-GEMM, cells were plated in 35 mm Petri dishes containing 1.2% methylcellulose (Stem Cell Technology, Vancouver, Canada), 20% FCS, BSA, IL2, IL3, 1.5 U erythropoietin (Eprex; Cilag, Brussels, Belgium) and alpha-monothioglycerol. Cultures were performed in duplicate and incubated in a humidified incubator containing 5% CO 2 in air at 37°C. After 14 days the cultures were scored for the presence of colonies by using an inverted microscope as described previously.
33,35
Cobblestone-area forming cell (CAFC) assay
To determine the recovery of functional immature progenitor cells after CCE the CAFC assay, as described by Ploemacher et al, 32 was performed. Briefly, stromal cells were prepared by seeding 10 3 cells of the FBMD-1 cell line from log-phase cultures into flat bottom 96-well plates (Falcon, Franklin Lakes, NY, USA) in IMDM (Gibco) supplemented with 10% FCS (Summit, Fort Collins, CO, USA), 5% horse serum (Integro, Zaandam, The Netherlands), 10 −4 mol/l ␤-mercaptoethanol (Merck, Darmstadt, Germany), 10 −5 mol/l hydrocorticosone 21-hemisuccinate (Sigma, St Louis, MO, USA), penicillin (100 U/ml; Gibco) and streptomycin (100 g/ml; Gibco). When cultures reached confluence the CCE cell fractions were inoculated on to this stromal layer in a limiting dilution set up with 2.5 × 10 6 to 5 × 10 4 cells per well in the first dilution. Twelve two-fold dilutions with 15 replicate wells per dilution were applied for each sample. The same culture medium as used for culturing the cell line was added, but was supplemented with IL3 (10 ng/ml; Gist Brocades, Delft, The Netherlands) and G-CSF (20 ng/ml; Roche, Mijdrecht, The Netherlands). The percentage of wells with at least one hematopoietic clone of at least five phasecontrast dark cells (ie cobble-stone area) beneath the stromal layer was determined at week 2, 4 and 6 of culture. The CAFC frequencies were calculated using Poisson statistics. 36 
Clinical outcome after stem cell transplantation
Initial engraftment was monitored by daily evaluation of hematologic parameters. Engraftment was defined by a WBC Ͼ1.0 × 10 9 /l on 2 consecutive days and a platelet count of Ͼ20 × 10 9 /l unsupported. As GVHD prophylaxis patients received cyclosporine A (CsA) 3 mg/kg/day by continuous infusion from days −1 to +14, followed by 2 mg/kg/day as a continuous i.v. infusion until day 21. Beyond day 21, CsA was administered orally (6 mg/kg/day) until 12 weeks after transplantation. CsA was gradually tapered and stopped 16 weeks post-transplantation.
Acute and chronic GVHD were classified from grade I to IV and as limited or extensive, respectively. 37, 38 Statistically significant differences were determined by Fisher's exact test or Mann-Whitney U test analysis.
Results
Cell separation in CCE
Maximally 2.0-2.5 × 10 9 MNC derived from BM or PBSC from sibling donors were loaded in each CCE chamber and separated. By reducing the rotor speed stepwise, starting at 3000 r.p.m., cells were collected in 13 fractions including the RO fraction ( Figure 1) . Apart from the RO fraction all other fractions consisted of comparable numbers of cells implicating that the percentage of cells is a reliable parameter for evaluation of the CCE pattern. High speed fractions consisted mainly of B (CD19 + ) and T (CD3 + ) cells (from 3000 to 2600 r.p.m.). NK (CD3 − /CD56 + ) cells were enriched in the intermediate fractions (2600 to 2400 r.p.m.). Although low amounts of progenitor cells, expressed as CD34-positive cells, were found in the high speed fractions (3000 to 2700 r.p.m.) most CD34
+ cells were collected in the lower speed fractions (р2500 r.p.m.). The percentage of CD34
+ cells was lower in the RO fraction than in the low speed fractions (data not shown). However, due to the high cell numbers in this fraction (approximately 10-times higher than the other fractions) the absolute number of CD34 + cells was the highest. BM and PBSC separations showed comparable profiles.
The separation pattern of CD34-positive cells was comparable with the profiles of the more and less mature erythroid and myeloid hematopoietic progenitor cells (HPC) determined in assays of CFU-GM, BFU-E and CFU-GEMM (Figure 2) .
Recoveries of different cell populations after CCE
A mean number of 6.0 Ϯ 0.1 × 10 9 BM cells and 36.8 Ϯ 8.6 × 10 9 PBSC were processed in one and four CCE runs, respectively. After determination of the number of T cells in each fraction the graft was composed by adding one or more low speed fractions to the RO fraction in order to obtain a BM graft with a fixed number of 0.7 × 10 6 T cells per kg body weight. Due to the combination of fractions derived from four CCE runs the number of T cells in PBSC grafts averages out at 4.4 × 10 6 per kg body weight (Table 1 ). The recovery of the different cell populations was determined by comparing the graft content with the pooled excluded lymphocyte fractions and the initial MNC population before CCE (Figure 3 ). The recovery of CD34 + cells, CFU-GM and BFU-E was lower in PBSC grafts than in BM grafts (54%, 46% and 37% vs 90%, 89% and 68%, respectively). However, the recipients of PBSC grafts received significantly more NC, CD34
+ cells, CFU-GM and BFU-E (PϽ 0.001) ( Table 1 ). The cloning efficiency of CFU-GM in BM and PBSC was determined by calculation of the number of CD34 + cells responsible for the formation of one CFU-GM colony. The clonogenic capacity of PBSC appeared to be higher than that of BM ( Table 1) .
The number of infused T cells per kg body weight was also higher in PBSC recipients than in BM recipients (4.4 × 10 6 vs 0.7 × 10 6 , respectively; P Ͻ 0.001).
CCE separation of CD34 + subpopulations
The CCE separation procedure is mainly based on size and density of cells. As a result smaller cells are collected in the high speed fractions. This implies that small CD34 + cells that may represent resting and more immature progenitor cells with long-term repopulating capacity, are excluded from graft fractions. As a consequence the incidence of graft failure and secondary graft rejection may be increased after transplantation of grafts that are lymphocyte-depleted using CCE.
To study which fractions mainly contain these immature progenitor cells, the separation patterns of CD34 + subpopulations were investigated using flow cytometry. As expected, flow cytometrical analysis of forward and side scatter of the CD34
+ gated cell population revealed that the CD34 + cells found in the higher speed fractions expressed lower forward and side scatter properties than CD34 + cells collected in the lower speed fractions (data not shown). In order to study whether cells collected in high speed fractions were immature progenitors, separation patterns of CD34 + subpopulations were more extensively investigated in three CCE separations of BM and PBSC transplants. Cells derived from the different CCE fractions were labeled with MoAbs directed against lineage-specific antigens and analyzed by flow cytometry of two-or three-color immunofluorescence (Figures 4 and 5) . Patterns of the investigated CD34 + subpopulations were comparable. Most cells of the CD34 + subpopulations were collected in fractions р2500 r.p.m. Though the RO fraction contained a low percentage of CD34
+ cells the absolute number in this fraction appeared to be the highest of all fractions due to the high total number of nucleated cells implying that most progenitors were retained in the final graft. The CD34 + population consisted mainly of mature progenitors represented by CD38 + , HLA-DR + and CD13 + cells (Figure 4) . The percentage of lymphocyte progenitors was lower than 0.5% in all fractions and consisted mainly of B cell progenitors (CD34/CD19 + ). The T cell progenitors, characterized by CD34/CD7 + subpopulations, could not be detected reliably (Ͻ0.1%; data not shown).
The percentage of more immature progenitor cell populations, characterized by lacking CD38 and HLA-DR expression, was Ͻ0.5% in all fractions of BM and PBSC separations. However, most immature progenitor cells were collected in the low speed fractions and mainly in the RO fraction ( Figure 5 ). This profile was most pronounced in PBSC separations. This implies that a substantial number of immature progenitors were transplanted. Fifty-nine to 85% (mean 74%, 13.2 × 10 6 cells) of the CD34 + CD13 − HLA-DR − cells derived from the original BM harvest were retained in the graft. Forty to 72% (mean 55%) of the immature progenitor cells derived from the PBSC harvest were recovered in the graft.
Potency of CAFC formation in CCE fractions
To study the presence of immature progenitor cells with proliferating capacity CAFC assays were performed. The number of CAFC in the CCE fractions was determined at week 2, 4 and 6, representing different stages of (im)mature cells. The relative number of CAFCs in the different CCE fractions from BM and PBSC are shown in Figure 6 . Due to the variation in number of clones per patient a representative result of BM ( Figure 6a ) and PBSC (Figure 6b ) is depicted. The CAFC week 4 appeared to be present in a higher quantity than the CAFC week 2. The most immature cells represented the lowest number. The separation patterns of the different CAFC-week types in BM and PBSC were comparable. Most progenitors were collected in the low speed fractions (Ͻ2500 r.p.m.). The fraction with the highest number of CAFCs appeared to vary between the different subsets. Though separation differences were slight, more immature progenitor cells (CAFC week 6) were collected in a higher speed fraction than the less immature cells (CAFC week 2). The frequencies of CAFC in the RO fraction was low. However, the absolute numbers were the highest due to the high number of nucleated cells. The evident concentration of immature cells in the low speed fractions becomes clearer comparing the CAFC before CCE and CAFC in the ultimate grafts of BM and PBSC ( Figure 7) . Most immature cells were collected in the graft. Though the total number of CAFC in BM was lower the recovery appeared to be higher in comparison with PBSC (approximately 80% and 60%, respectively).
Clinical outcome after transplantation of BM and PBSC
Clinical outcome is given in Table 2 . The median day of WBC engraftment was 19 in BM recipients and 16 in PBSC recipients (P = 0.01). All patients engrafted within 26 days. The median day to reach a platelet count of Ͼ20 × 10 9 /l without support was 22 after BMT and 14 after PBSCT. One patient did not yet reach this level unsupported.
Though the median numbers of infused nucleated cells (Table 1) , the incidence and severity of acute GVHD did not differ significantly (Table 2) . Acute GVHD grade уIII occurred in 0 of 16 BM recipients and two of 12 PBSC recipients (P = 0.17). The onset of acute GVHD was also comparable with a median of 18 and 16 days after BMT and after PBSCT, respectively. Extensive chronic GVHD developed in four of 15 BM recipients and in three of nine patients transplanted with PBSC (P = 0.54).
Discussion
In contrast to various other T cell depletion techniques, CCE allows titration of an appropriate number of T cells per kg body weight to a graft based on the individual circumstances of each patient without triggering of cells. In this study, we compared the CCE separations of 16 BM and 12 PBSC transplants. We showed that CCE using our techniques allows processing of both stem cell sources with sufficient yield of mature and immature progenitor cells. These data are supported by our clinical studies regarding low incidence of graft failure within a normal time of engraftment in almost 500 transplanted patients. [10] [11] [12] [13] Graft failure occurred in approximately 3% of the HLA-identical sibling transplantations. No graft failure occurred in the patients of the present study groups. This is in contrast with the data of Noga et al 39 who found 10% graft failure and delayed engraftment in his patients after receiving an elutriated allograft. Our patients, however, received a higher T cell dose per kilogram body weight.
Though the number of infused T cells were significantly higher in PBSCT than in BMT, the incidence and severity of acute GVHD did not differ significantly. Due to the CCE separation principle which is based on the cell size and density, it may be speculated that in BMT as well as in PBSCT a number of larger T cells derived from the low speed fractions are infused that do not possess GVHD- inducing properties but engraftment facilitating activity. This hypothesis is still under investigation. Despite the low incidence of severe acute and extensive chronic GVHD, we observed a relatively low risk for relapse. 10, 12 However, the highest leukemia-free survival rates after BMT are seen in patients with grade I acute GVHD. 40 This anti-leukemia activity might also be due to the relatively high number of NK cells remaining in the graft after CCE (approximately 50% of the number in the initial transplant). 18 We showed that progenitor cells can be enriched in the larger cell CCE fractions. Several investigators, however, have shown in murine and feline models that primitive progenitors can be separated in the smaller cell fractions [41] [42] [43] suggesting a loss of immature progenitor cells based on their size and density. Yoder et al 41 demonstrated that different high proliferative potential colony-forming cells (HPP-CFC) can be identified by CCE separation based on growth factor responsiveness but their distribution profile differs between different strains of mice. Different HPP-CFC were only detected by increasing the number of CCE fractions and using higher rotor speed. This implies that comparison of CCE data from different species and different procedures might be complicated.
Herbein et al 19 and Wagner et al 29 demonstrated that less mature CD34
+ cells derived from human PBSC not coexpressing CD38 and lacking colony formation were mainly collected in smaller cell fractions. Nevertheless Grimm et al 44 showed that G-CSF mobilized PBSC are heterogeneous in size and density implicating a distribution over all CCE fractions. Chang et al 28 found as a result of experimental CCE separations of BM, a removal of 96% of T cells accompanied with a loss of 65% of HPP-CFC and long-term culture-initiating cells. Comparable data were found by Wagner et al 29 in experimental PBSC separations. Therefore we have investigated the separation patterns of mature and immature progenitors derived from BM and PBSC by using a Curamee 3000 system containing a multi-chamber rotor. Our results and those from other investigators using the same system 20, 30, 31 are in contrast with the above-mentioned authors who have all used the Beckmann JE-5.0 or JE-6B rotor system.
We found that CD34 + cells from BM and PBSC harvests could be effectively enriched in the low speed fractions when applying CCE within a speed range from 3000 to 2200 r.p.m. These results supported the data obtained in clonogenic assays of CFU-GM, BFU-E and CFU-GEMM. However, the CD34 + cells elutriated in the high speed fractions showed a lower forward and side scatter expression in flow cytometric analysis (data not shown) suggesting a quiescent status of these hematopoietic cells as found by Wagner et al. 29 To exclude that this minor population, that was collected in the lymphocyte-enriched fractions, consisted of the main proportion of immature progenitors, all cell fractions were evaluated in flow cytometry and in CAFC assays. The separation profiles of BM and PBSC appeared to be similar, but the highest concentration of PBSC CD34
+ cells tended to occur in lower speed fractions in comparison with BM CD34 + cells. This finding is in agreement with the results of Chang et al 45 who showed a shift to higher flow-rate fractions for PBSC CD34
+ cells in the Beckmann JE-5.0 elutriator.
Though the cells with the immature phenotype of CD34
− and CD34 + /CD13 − /HLA-DR − were also present in the lymphocyte-enriched fractions, the highest numbers of these cells were collected in the graft fractions. This was also most pronounced in PBSC. These results were supported by the CAFC assays. Using this assay mature and primitive progenitor cells that represent longterm repopulating cells in vitro can be distinguished and quantified. 45, 46 The evident concentration of immature cells in the low speed fractions becomes clear in the comparison between the CAFC before CCE and CAFC in the ultimate grafts of BM and PBSC (Figure 7 ). Though the yield in BM was lower the recovery of CAFC appeared to be higher in comparison with PBSC (approximately 80% and 60%, respectively).
Differences between our results and those of Chang et al 28 regarding the elutriation profile of immature progenitor cells might be due to the different equipments used (Curamee vs Beckmann JE-5, respectively). However, the loss of HPP-CFC and LTC-IC described by Chang et al is not reflected in clinical studies in which the same equipment was used. 14, 17 The procedure of CCE strongly influences the separation profile. Variation of rotor speed instead of increasing the flow rate is recommended because reduction of rotor speed is far more adjustable than is flow rate (Plas et al, unpublished data) . A number of differences exist between our procedure and those applied by Chang et al. Firstly, Chang et al elutriated the BM cell populations under a constant centrifugal speed and increasing flow rates. In the clinical setting, 14, 17 however, a constant flow with decreasing centrifugal speed was used. Secondly, a higher starting speed rate, as used in our setting, advantageously affects the separation process. 41 We loaded the CCE rotor and started the procedure at 3000 r.p.m. Thirdly, the cell load, the volume and the shape of the separation chamber was also different. Lutz et al 47 showed that a chamber which is calculated according to the hydrodynamic boundaries of the CCE separation improves the separation selectivity. Chang et al processed relatively small amounts of cells while in the clinical settings larger numbers of cells were separated (up to 2 × 10 9 cells/chamber in our setting). Nevertheless, Kwekkeboom et al 31 also found a concentration of progenitor cells in the lower speed fractions when relatively small numbers of PBSC were loaded.
These data confirm that CCE is a reliable method to deplete T cells from BM transplants without substantial loss of immature and mature progenitor cells. Furthermore CCE might be considered a feasible method to process PBSC transplants. Though the number of cells that must be processed in PBSCT is much higher than in BMT the separation patterns of progenitor cells are comparable. However, due to the higher number of T cells and the lower concentration of CD34
+ cells in the initial harvest, more CCE runs have to be performed resulting in a laborious procedure. Nevertheless, CCE allows compiling a graft with a sufficient number of stem cells to ensure engraftment and with an appropriate number of T cells adjusted to each patient individually. This results in a low incidence of graft failure and a relatively low incidence of severe GVHD.
